Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NISCHALA AMMANNAGARI

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1033405154
CMS profile
5703502
Location
ALBANY, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$2,800.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $2,800.00 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $2,800.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NISCHALA AMMANNAGARI

NPI 1033405154 · CMS profile ID 5703502

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ALBANY, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1033405154?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NISCHALA AMMANNAGARI, NPI 1033405154, CMS profile ID 5703502. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033405154?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). NISCHALA AMMANNAGARI, NPI 1033405154, CMS profile ID 5703502. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033405154?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
NISCHALA AMMANNAGARI, NPI 1033405154, CMS profile ID 5703502, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1033405154?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $2,800.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $2,800.0011/26/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735812129 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,072.24 4
PY2020 $2,800.00 1
PY2021 $36.92 2
PY2022 $14.84 1
PY2024 $17.02 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $885.00 3
PY2024 Principal investigator $5,173.00 8
PY2023 Principal investigator $12,922.20 19
PY2022 Principal investigator $30,379.00 29
PY2021 Principal investigator $256,912.40 96
PY2020 Principal investigator $44,761.36 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

96 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Seagen Inc. $3,430.00 12/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675169
Principal investigator 1 Seagen Inc. $30.00 12/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675171
Principal investigator 1 Seagen Inc. $188.00 12/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675177
Principal investigator 1 Seagen Inc. $40.00 12/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675179
Principal investigator 1 Seagen Inc. $30.00 12/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675289
Principal investigator 1 Seagen Inc. $4,123.96 12/09/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675363
Principal investigator 1 Seagen Inc. $4,123.96 12/09/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675549
Principal investigator 1 Seagen Inc. $4,123.96 11/18/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675361
Principal investigator 1 Seagen Inc. $4,123.96 11/18/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675547
Principal investigator 1 Seagen Inc. $2,150.00 11/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675159
Principal investigator 1 Seagen Inc. $4,123.96 11/02/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675359
Principal investigator 1 Seagen Inc. $4,123.96 11/02/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675545
Principal investigator 1 Seagen Inc. $2,150.00 10/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675135
Principal investigator 1 Seagen Inc. $295.00 10/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675139
Principal investigator 1 Seagen Inc. $2,150.00 10/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675259
Principal investigator 1 Seagen Inc. $956.00 10/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675261
Principal investigator 1 Seagen Inc. $295.00 10/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675273
Principal investigator 1 Seagen Inc. $4,123.96 10/07/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675357
Principal investigator 1 Seagen Inc. $4,123.96 10/07/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675543
Principal investigator 1 Seagen Inc. $4,123.96 09/20/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675355
Principal investigator 1 Seagen Inc. $4,123.96 09/20/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675541
Principal investigator 1 Seagen Inc. $3,230.00 09/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675257
Principal investigator 1 Seagen Inc. $4,123.96 08/26/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675353
Principal investigator 1 Seagen Inc. $4,123.96 08/26/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675539
Principal investigator 1 Seagen Inc. $2,145.00 08/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675223
Principal investigator 1 Seagen Inc. $1,950.00 08/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675233
Principal investigator 1 Seagen Inc. $4,123.96 08/09/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675351
Principal investigator 1 Seagen Inc. $4,123.96 08/09/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675537
Principal investigator 1 Seagen Inc. $4,123.96 07/19/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675349
Principal investigator 1 Seagen Inc. $4,123.96 07/19/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675535
Principal investigator 1 Seagen Inc. $295.00 07/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675191
Principal investigator 1 Seagen Inc. $2,140.00 07/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675205
Principal investigator 1 Seagen Inc. $1,841.00 07/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675211
Principal investigator 1 Seagen Inc. $956.00 07/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675331
Principal investigator 1 Seagen Inc. $4,123.96 06/24/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675109
Principal investigator 1 Seagen Inc. $4,123.96 06/24/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675133
Principal investigator 1 Seagen Inc. $3,230.00 06/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675003
Principal investigator 1 Seagen Inc. $3,636.00 06/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675007
Principal investigator 1 Seagen Inc. $2,150.00 06/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675025
Principal investigator 1 Seagen Inc. $4,123.96 06/07/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675107
Principal investigator 1 Seagen Inc. $4,123.96 06/07/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675131
Principal investigator 1 Seagen Inc. $4,123.96 05/19/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675105
Principal investigator 1 Seagen Inc. $4,123.96 05/19/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675129
Principal investigator 1 Seagen Inc. $2,610.00 05/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674989
Principal investigator 1 Seagen Inc. $2,851.00 05/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674993
Principal investigator 1 Seagen Inc. $1,950.00 05/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674995
Principal investigator 1 Seagen Inc. $4,123.96 05/06/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675103
Principal investigator 1 Seagen Inc. $4,123.96 05/06/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675127
Principal investigator 1 Seagen Inc. $4,123.96 04/27/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675101
Principal investigator 1 Seagen Inc. $4,123.96 04/27/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675125
Principal investigator 1 Seagen Inc. $188.00 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674849
Principal investigator 1 Seagen Inc. $956.00 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674855
Principal investigator 1 Seagen Inc. $450.00 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674861
Principal investigator 1 Seagen Inc. $3,636.00 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674863
Principal investigator 1 Seagen Inc. $2,140.00 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674865
Principal investigator 1 Seagen Inc. $1,445.00 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674871
Principal investigator 1 Seagen Inc. $2,000.00 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674873
Principal investigator 1 Seagen Inc. $85.00 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674875
Principal investigator 1 Seagen Inc. $500.00 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674877
Principal investigator 1 Seagen Inc. $40.00 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674879
Principal investigator 1 Seagen Inc. $2,145.00 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674881
Principal investigator 1 Seagen Inc. $2,610.00 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674883
Principal investigator 1 Seagen Inc. $30.00 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674965
Principal investigator 1 Seagen Inc. $4,263.00 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674967
Principal investigator 1 Seagen Inc. $2,865.00 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674969
Principal investigator 1 Seagen Inc. $295.00 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674973
Principal investigator 1 Seagen Inc. $1,445.00 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675059
Principal investigator 1 Seagen Inc. $1,445.00 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675061
Principal investigator 1 Seagen Inc. $1,445.00 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675065
Principal investigator 1 Seagen Inc. $1,445.00 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675067
Principal investigator 1 Seagen Inc. $2,000.00 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675069
Principal investigator 1 Seagen Inc. $1,445.00 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675071
Principal investigator 1 Seagen Inc. $4,123.96 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675099
Principal investigator 1 Seagen Inc. $4,123.96 04/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675123
Principal investigator 1 Seagen Inc. $4,123.96 04/07/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675097
Principal investigator 1 Seagen Inc. $4,123.96 04/07/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675121
Principal investigator 1 Seagen Inc. $4,123.96 03/25/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675093
Principal investigator 1 Seagen Inc. $4,123.96 03/25/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675117
Principal investigator 1 Seagen Inc. $4,123.96 03/16/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675091
Principal investigator 1 Seagen Inc. $4,123.96 03/16/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675115
Principal investigator 1 Seagen Inc. $4,123.96 03/09/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675089
Principal investigator 1 Seagen Inc. $4,123.96 03/09/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675113
Principal investigator 1 Seagen Inc. $4,123.96 02/22/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675087
Principal investigator 1 Seagen Inc. $4,123.96 02/22/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675111
Principal investigator 1 Seagen Inc. $188.00 02/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674835
Principal investigator 1 Seagen Inc. $40.00 02/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674837
Principal investigator 1 Seagen Inc. $1,841.00 02/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674839
Principal investigator 1 Seagen Inc. $4,263.00 02/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674841
Principal investigator 1 Seagen Inc. $2,000.00 02/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674843
Principal investigator 1 Seagen Inc. $1,445.00 02/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674845
Principal investigator 1 Seagen Inc. $2,865.00 02/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674847
Principal investigator 1 Seagen Inc. $1,445.00 02/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675043
Principal investigator 1 Seagen Inc. $1,445.00 02/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675045
Principal investigator 1 Seagen Inc. $4,123.96 01/26/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675095
Principal investigator 1 Seagen Inc. $4,123.96 01/26/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792675119
Principal investigator 1 Seagen Inc. $2,851.00 01/15/2021 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792674831